Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chubb Ltd (CB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Chubb Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Chubb Ltd trades at $347.65 (market cap $133.90B), while Zimmer Biomet Holdings Inc trades at $95.01 (market cap $18.55B). The key difference: Chubb Ltd is far larger — about 7.2× Zimmer Biomet Holdings Inc's market cap, and Chubb Ltd pays the higher dividend (1.18%). Which is the better fit depends on your goals.

CBZBH
Market Cap
$133.90B$18.55B
Sector
FinancialsHealth
52-Week High
$363.50$107.71
52-Week Low
$268.20$79.58
Enterprise Value
$154.74B$25.61B
Dividend Yield
1.18%0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chubb Ltd

Chubb Limited (CB) trades at $348.3, down 0.57% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 12.3, net income margin of 17.96%, and consistent earnings beats in recent quarters. Recent news highlights partnerships and leadership appointments, supporting growth prospects. Cash flow trends indicate stable operations, with 2026 net cash flow projected at $382 million.

The outlook for CB is positive, driven by disciplined underwriting, premium growth, and rising investment income. Risks include competitive pressures and macroeconomic volatility. Analysts maintain a buy consensus with a $366.83 price target, suggesting upside potential. The stock presents a value opportunity with solid dividend income, though investors should monitor underwriting performance and market conditions.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

About Chubb Ltd

ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.

Read more on CB

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH